ORTHO-NOVUM 7/7/7-28
LOE ApproachingNDAORAL-28TABLET
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 7/7/7-28 is an oral contraceptive tablet containing norethindrone and ethinyl estradiol in a triphasic formulation. It prevents pregnancy through hormonal suppression of ovulation. The 28-day pack includes 21 active tablets followed by 7 placebo tablets.
LOE Approaching
Mature franchise approaching loss of exclusivity with moderate competitive pressure (30), signaling consolidation and focus on retained market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 7/7/7-28 represents a defensive, consolidation-focused career move rather than a growth opportunity. Roles emphasize market retention, cost optimization, and generic transition planning with limited upside potential.
Brand ManagerField Sales Representative
Worked on ORTHO-NOVUM 7/7/7-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.